Last reviewed · How we verify
Clindamycin 1% Gel
At a glance
| Generic name | Clindamycin 1% Gel |
|---|---|
| Sponsor | University of Southern California |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Metronidazole 2% Gel Versus Clindamycin 1% Gel for Moderate Acne Vulgaris (PHASE4)
- Experience With Topical Acne Treatment (EARLY_PHASE1)
- Effect of Intracanal Medicaments on Post-Operative Pain in Symptomatic Apical Periodontitis: An RCT (NA)
- Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields (PHASE2)
- A Study Assessing the Efficacy and Safety of Combined Use of Clascoterone 1% Cream and Duac Gel (Benzoyl Peroxide/Clindamycin) for the Treatment of Acne (PHASE4)
- Efficacy of Manuka Honey Nano-Formulation in the Treatment of Acne Vulgaris (NA)
- Clinical Study Between Two 1% Clindamycin/5% Benzoyl Peroxide Topical Gel Formulations (NA)
- Comparison of the Efficacy of Clindamycin Phosphate 1% Gel Versus Once-daily Dapsone 5% Gel in the Treatment of Moderate Acne Vulgaris (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clindamycin 1% Gel CI brief — competitive landscape report
- Clindamycin 1% Gel updates RSS · CI watch RSS
- University of Southern California portfolio CI